StockNews.com started coverage on shares of iCAD (NASDAQ:ICAD - Free Report) in a research note published on Saturday morning. The brokerage issued a sell rating on the technology company's stock.
A number of other research firms have also commented on ICAD. Craig Hallum lowered iCAD from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. BTIG Research lowered iCAD from a "buy" rating to a "neutral" rating in a report on Wednesday, April 16th. Finally, Laidlaw restated a "hold" rating on shares of iCAD in a report on Thursday, April 17th.
View Our Latest Stock Report on iCAD
iCAD Trading Up 1.9 %
ICAD stock traded up $0.06 during trading hours on Friday, hitting $3.48. 143,000 shares of the stock were exchanged, compared to its average volume of 376,929. iCAD has a 12 month low of $1.18 and a 12 month high of $3.78. The firm has a market capitalization of $95.34 million, a P/E ratio of -26.73 and a beta of 1.78. The company has a 50-day simple moving average of $2.37 and a two-hundred day simple moving average of $2.23.
iCAD (NASDAQ:ICAD - Get Free Report) last released its earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.02. The firm had revenue of $5.41 million during the quarter, compared to analysts' expectations of $4.72 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.
Hedge Funds Weigh In On iCAD
Several institutional investors and hedge funds have recently bought and sold shares of the company. Perritt Capital Management Inc boosted its holdings in iCAD by 1.9% in the 4th quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company's stock worth $346,000 after buying an additional 3,600 shares during the period. waypoint wealth counsel raised its stake in shares of iCAD by 44.0% during the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company's stock valued at $26,000 after purchasing an additional 4,400 shares during the period. Wells Fargo & Company MN boosted its stake in iCAD by 51.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock worth $72,000 after purchasing an additional 13,402 shares during the period. Thompson Davis & CO. Inc. purchased a new position in iCAD during the 4th quarter valued at about $31,000. Finally, Geode Capital Management LLC increased its position in shares of iCAD by 6.6% during the fourth quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company's stock valued at $506,000 after buying an additional 17,059 shares during the period. 24.61% of the stock is owned by institutional investors.
iCAD Company Profile
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Articles
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
